Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/09031936.00201012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Aerosol Inhalation of Colistin Sulfate for the Treatment of Carbapenem-Resistant Infection in the Peri-Operative Period of Liver Transplantation: A Single-Center Retrospective Study.
Surg Infect (Larchmt)
December 2024
Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou, P.R. China.
This study intended to evaluate the clinical efficacy and safety of colistin sulfate aerosol inhalation in combination with ceftazidime-avibactam for the treatment of pulmonary carbapenem-resistant (CRKP) infection during the peri-operative period of liver transplantation. A retrospective analysis was designed to investigate 52 patients who developed pulmonary CRKP infection after liver transplantation between December 1, 2019, and November 30, 2022. On the basis of whether they received colistin sulfate aerosol inhalation, the patients were divided into the treatment group ( = 29) and the control group ( = 23).
View Article and Find Full Text PDFEvaluating the Efficacy of Inhaled Colistin via Two Nebulizer Types in Ventilator-Associated Pneumonia: Prospective Randomized Trial.
Antibiotics (Basel)
November 2024
Division of Pulmonary and Critical Care Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 33342, Taiwan.
Article Synopsis
- A study tested the effectiveness of inhaled colistin in treating ventilator-associated pneumonia caused by resistant bacteria, using two types of nebulizers: a vibrating mesh nebulizer (VMN) and a jet nebulizer (JN).
- Patients receiving intravenous (IV) colistin inhalation were randomly assigned to either nebulizer type and compared to a control group receiving IV only over a period of 7 to 10 days, with a focus on clinical improvement.
- While VMN delivered a higher dose of colistin in lab tests, both nebulizers showed similar clinical outcomes in patients, showing significant benefits over the IV-only group.
Therapeutic Interventions for Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.
J Clin Med
October 2024
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra 11961, Saudi Arabia.
() poses a significant threat to individuals with cystic fibrosis (CF), as this bacterium is highly adaptable and resistant to antibiotics. While early-stage infections can often be eradicated with aggressive antibiotic therapy, chronic infections are nearly impossible to eliminate and require treatments that focus on long-term bacterial suppression. Without such suppression, these persistent infections can severely damage the lungs, leading to serious complications and a reduced life expectancy for CF patients.
View Article and Find Full Text PDFAssessment of inhaled cationic antibiotics in an in vitro model of Pseudomonas aeruginosa lung biofilm.
Microb Pathog
December 2024
Université de Poitiers, PHAR2, Inserm U1070, Poitiers, France. Electronic address:
Objectives: This study aimed to evaluate the efficacy of inhaled cationic antibiotics, including tobramycin (TOB) and colistin (CST), using an in vitro alginate bead model that simulates Pseudomonas aeruginosa lung biofilms.
Methods: Bioluminescent P. aeruginosa were encapsulated within alginate beads and dispersed in either Mueller-Hinton broth (MHB) or artificial sputum medium (ASM).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!